Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John S Bevan

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
The Journal of Clinical Endocrinology and Metabolism|December 23, 2004
Clinical review: The antitumoral effects of somatostatin analog therapy in acromegalyJohn S Bevan
Nature Clinical Practice. Endocrinology & Metabolism|August 26, 2006
Can dopamine agonists prevent postoperative remnant enlargement in nonfunctioning pituitary adenomas?John S Bevan
Clinical Medicine (London, England)|June 14, 2013
Pituitary incidentalomaJohn S Bevan
Pituitary|March 14, 2008
Preoperative assessment for pituitary surgeryOlivia Pereira, John S Bevan
Clinical Endocrinology|April 27, 2013
Type 1 drug hypersensitivity following first dose of pegvisomantJubbin J Jacob, John S Bevan
Clinical Endocrinology|July 22, 2014
Should all patients with acromegaly receive somatostatin analogue therapy before surgery and, if so, for how long?Jubbin J Jacob, John S Bevan
Endocrine Connections|September 29, 2017
Morbidity and mortality in patients with hyperprolactinaemia: the PROLEARS studyEnrique Soto-Pedre, Paul J Newey, John S Bevan, et al.
Clinical Endocrinology|November 23, 2016
Glucose and lipid levels with lanreotide autogel 120 mg in treatment-naïve patients with acromegaly: data from the PRIMARYS studyPhilippe J Caron, Stephan Petersenn, Aude Houchard, et al.
The Cochrane Database of Systematic Reviews|January 22, 2010
Antithyroid drug regimen for treating Graves' hyperthyroidismPrakash Abraham, Alison Avenell, Susan C McGeoch, et al.
European Journal of Endocrinology|September 29, 2005
A systematic review of drug therapy for Graves' hyperthyroidismPrakash Abraham, Alison Avenell, Christine M Park, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
The Journal of Clinical Endocrinology and Metabolism|December 23, 2004
Clinical review: The antitumoral effects of somatostatin analog therapy in acromegalyJohn S Bevan
Nature Clinical Practice. Endocrinology & Metabolism|August 26, 2006
Can dopamine agonists prevent postoperative remnant enlargement in nonfunctioning pituitary adenomas?John S Bevan
Clinical Medicine (London, England)|June 14, 2013
Pituitary incidentalomaJohn S Bevan
Pituitary|March 14, 2008
Preoperative assessment for pituitary surgeryOlivia Pereira, John S Bevan
Clinical Endocrinology|April 27, 2013
Type 1 drug hypersensitivity following first dose of pegvisomantJubbin J Jacob, John S Bevan
Clinical Endocrinology|July 22, 2014
Should all patients with acromegaly receive somatostatin analogue therapy before surgery and, if so, for how long?Jubbin J Jacob, John S Bevan
Endocrine Connections|September 29, 2017
Morbidity and mortality in patients with hyperprolactinaemia: the PROLEARS studyEnrique Soto-Pedre, Paul J Newey, John S Bevan, et al.
Clinical Endocrinology|November 23, 2016
Glucose and lipid levels with lanreotide autogel 120 mg in treatment-naïve patients with acromegaly: data from the PRIMARYS studyPhilippe J Caron, Stephan Petersenn, Aude Houchard, et al.
The Cochrane Database of Systematic Reviews|January 22, 2010
Antithyroid drug regimen for treating Graves' hyperthyroidismPrakash Abraham, Alison Avenell, Susan C McGeoch, et al.
European Journal of Endocrinology|September 29, 2005
A systematic review of drug therapy for Graves' hyperthyroidismPrakash Abraham, Alison Avenell, Christine M Park, et al.
Pageof 3